IN THE CLAIMS:

Please cancel Claims 1-20 with prejudice and substitute the following: Claims 1-20 (Cancelled)

- 21. A method of treating mucopolysaccharide disease in a patient in need thereof comprising administering a therapeutically effective amount of an inhibitor of glucosylceramide synthesis.
- 22. The method according to claim 21 wherein the mucopolysaccharide disease is selected from the group consisting of MPS I (MPS IH, IS or IH/S), MPS II, MPS IIIA, IIIB, IIIC or IIID, MPS IVA or IVB, MPS VI and MPS VII.
- 23. The method according to claim 21 wherein the inhibitor is an inhibitor of ceramide glucosyltransferase.
- 24. The method according to claim 21 wherein the inhibitor is an imino sugar.
- 25. The method according to claim 24 wherein the inhibitor is N-butyldeoxynojirimycin or N-butyldeoxygalactonojirimycin.
- 26. The method according to claim 25 wherein the inhibitor is N-butyldeoxynojirimycin.
- 27. The method according to claim 21 wherein the inhibitor is a nucleic acid coding for a protein or peptide capable of inhibiting glucosylceramide synthesis, or an antisense sequence or catalytic RNA capable of interfering with the expression of enzymes responsible for glucosylceramide synthesis.
- 28. A method of reducing neuronal glycolipid storage in mucopolysaccharide disease in a patient in need thereof comprising administering a therapeutically effective amount of an inhibitor of glucosylceramide synthesis.
- 29. The method according to claim 28 wherein the mucopolysaccharide disease is selected from the group consisting of MPS I (MPS III, III), MPS III, MPS IIIA, IIIB, IIIC or IIID, MPS IVA or IVB, MPS VI and MPS VII.
- 30. The method according to claim 28 wherein the inhibitor is an inhibitor of ceramide glucosyltransferase.
- 31. The method according to claim 28 wherein the inhibitor is an imino sugar.
- 32. The method according to claim 31 wherein the inhibitor is N-butyldeoxynojirimycin or N-butyldeoxygalactonojirimycin.

- 33. The method according to claim 32 wherein the inhibitor is N-butyldeoxynojirimycin.
- 34. The method according to claim 28 wherein the inhibitor is a nucleic acid coding for a protein or peptide capable of inhibiting glucosylceramide synthesis, or an antisense sequence or catalytic RNA capable of interfering with the expression of enzymes responsible for glucosylceramide synthesis.
- 35. A method of treating mucopolysaccharide disease in a patient in need thereof comprising administering a therapeutically effective amount of an agent capable of increasing the rate of neuronal glycolipid degradation.